
Neurones S.A (NRO) | Financial Analysis & Statements
Neurones S.A. | Mid-cap | Technology
Neurones S.A. | Mid-cap | Technology
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
725.7M
Total Liabilities
289.5M
Shareholders Equity
436.2M
Debt to Equity
0.66
Cash Flow Metrics
Revenue & Profitability Trend
Neurones S.A Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 810.4M | 741.2M | 665.4M | 579.9M | 524.5M |
Cost of Goods Sold | 304.2M | 284.5M | 256.2M | 231.3M | 212.0M |
Gross Profit | 506.2M | 456.7M | 409.2M | 348.6M | 312.4M |
Gross Margin % | 62.5% | 61.6% | 61.5% | 60.1% | 59.6% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | - | 170.8M | 150.7M |
Other Operating Expenses | 286.4M | 251.1M | 218.5M | 177.6M | 159.4M |
Total Operating Expenses | 286.4M | 251.1M | 218.5M | 348.4M | 310.1M |
Operating Income | 78.0M | 75.0M | 71.9M | 61.6M | 51.1M |
Operating Margin % | 9.6% | 10.1% | 10.8% | 10.6% | 9.7% |
Non-Operating Items | |||||
Interest Income | 11.8M | 5.9M | 1.7M | 1.2M | 905.0K |
Interest Expense | 1.8M | 1.4M | 1.7M | 966.0K | 1.0M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 88.1M | 80.8M | 72.9M | 61.8M | 53.6M |
Income Tax | 24.9M | 22.2M | 21.1M | 18.8M | 18.6M |
Effective Tax Rate % | 28.2% | 27.5% | 28.9% | 30.5% | 34.7% |
Net Income | 63.2M | 58.6M | 51.8M | 42.9M | 35.0M |
Net Margin % | 7.8% | 7.9% | 7.8% | 7.4% | 6.7% |
Key Metrics | |||||
EBITDA | 107.3M | 97.4M | 90.4M | 77.6M | 68.7M |
EPS (Basic) | €2.17 | €2.04 | €1.83 | €1.56 | €1.27 |
EPS (Diluted) | €2.16 | €2.03 | €1.82 | €1.56 | €1.27 |
Basic Shares Outstanding | 24272142 | 24237983 | 24222972 | 24215658 | 24239282 |
Diluted Shares Outstanding | 24272142 | 24237983 | 24222972 | 24215658 | 24239282 |
Income Statement Trend
Neurones S.A Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 326.5M | 297.8M | 272.1M | 265.2M | 266.6M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 172.5M | 174.3M | 167.0M | 138.7M | 131.4M |
Inventory | 267.0K | 709.0K | 353.0K | 887.0K | 635.0K |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 588.1M | 545.8M | 506.6M | 464.1M | 449.1M |
Non-Current Assets | |||||
Property, Plant & Equipment | 68.1M | 66.1M | 60.4M | 49.3M | 44.1M |
Goodwill | 114.7M | 108.2M | 91.4M | 90.6M | 86.3M |
Intangible Assets | 1.7M | 1.2M | 763.0K | 1.2M | 942.0K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | - | - | - | - |
Total Non-Current Assets | 137.6M | 130.3M | 109.6M | 103.7M | 100.8M |
Total Assets | 725.7M | 676.1M | 616.2M | 567.8M | 549.9M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 58.3M | 44.0M | 42.9M | 37.7M | 32.7M |
Short-term Debt | 12.5M | 13.1M | 8.2M | 7.5M | 6.9M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 19.8M | 16.6M | - | 1.0K | - |
Total Current Liabilities | 252.7M | 228.9M | 207.1M | 184.6M | 161.4M |
Non-Current Liabilities | |||||
Long-term Debt | 29.5M | 30.9M | 27.4M | 27.8M | 27.2M |
Deferred Tax Liabilities | - | - | - | - | 0 |
Other Non-Current Liabilities | - | - | - | - | - |
Total Non-Current Liabilities | 36.9M | 37.4M | 33.5M | 30.3M | 29.4M |
Total Liabilities | 289.5M | 266.3M | 240.6M | 214.9M | 190.8M |
Equity | |||||
Common Stock | 9.7M | 9.7M | 9.7M | 9.7M | 9.7M |
Retained Earnings | 52.6M | 49.4M | - | - | - |
Treasury Stock | 201.0K | 448.0K | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 436.2M | 409.8M | 375.6M | 352.9M | 359.0M |
Key Metrics | |||||
Total Debt | 42.0M | 44.0M | 35.6M | 35.3M | 34.2M |
Working Capital | 335.5M | 316.9M | 299.5M | 279.6M | 287.6M |
Balance Sheet Composition
Neurones S.A Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 63.2M | 58.6M | 51.8M | 42.9M | 35.0M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | 5.1M | 4.4M | 3.4M | 2.0M | 1.6M |
Working Capital Changes | 0 | 0 | 0 | 0 | 0 |
Operating Cash Flow | 58.2M | 57.9M | 54.7M | 45.0M | 35.1M |
Investing Activities | |||||
Capital Expenditures | 260.0K | 77.0K | 56.0K | 156.0K | 71.0K |
Acquisitions | -6.6M | -3.5M | -809.0K | -3.7M | 15.0K |
Investment Purchases | -1.8M | -2.1M | -1.7M | -1.1M | -1.3M |
Investment Sales | 461.0K | 1.9M | 808.0K | 569.0K | 384.0K |
Investing Cash Flow | -7.7M | -3.6M | -1.7M | -4.0M | -820.0K |
Financing Activities | |||||
Share Repurchases | -28.0K | 0 | -107.0K | 0 | -1.2M |
Dividends Paid | -29.1M | -26.6M | -24.2M | -48.4M | -4.8M |
Debt Issuance | 5.1M | 6.4M | 68.0K | 15.0K | 143.0K |
Debt Repayment | -4.3M | -2.6M | -316.0K | -208.0K | -75.0K |
Financing Cash Flow | -18.1M | -17.9M | -24.6M | -48.3M | -4.3M |
Free Cash Flow | 72.3M | 54.1M | 44.4M | 57.9M | 60.1M |
Net Change in Cash | 32.4M | 36.5M | 28.5M | -7.3M | 30.0M |
Cash Flow Trend
Neurones S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
18.99
Forward P/E
17.95
Price to Book
2.54
Price to Sales
1.19
PEG Ratio
17.95
Profitability Ratios
Profit Margin
6.10%
Operating Margin
7.80%
Return on Equity
12.05%
Return on Assets
7.24%
Financial Health
Current Ratio
2.33
Debt to Equity
0.10
Beta
0.53
Per Share Data
EPS (TTM)
€2.08
Book Value per Share
€15.58
Revenue per Share
€33.39
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
nro | 992.4M | 18.99 | 2.54 | 12.05% | 6.10% | 0.10 |
Capgemini SE | 21.7B | 13.73 | 1.89 | 14.32% | 7.07% | 55.23 |
Sopra Steria | 3.2B | 11.50 | 1.60 | 14.37% | 4.76% | 63.80 |
Atos SE | 943.7M | 0.09 | - | 31.04% | 17.29% | 3.52 |
Aubay Société | 560.2M | 14.73 | 2.03 | 14.12% | 6.97% | 7.73 |
Infotel | 285.9M | 15.43 | 2.29 | 15.62% | 6.27% | 24.98 |
Financial data is updated regularly. All figures are in the company's reporting currency.